Piramal Consumer Healthcare bets on power brands, quick commerce for $200M by 2030
Piramal is pruning its FMCG portfolio to focus on Lacto Calamine, i-pill and new i-choose women's wellness line, leaning on premiumization, influencer marketing and quick commerce (over half of e-commerce sales) to nearly double FY26 revenue of ₹1,274 cr to $200M by 2030.
Piramal Consumer Healthcare is narrowing focus to power brands, premiumization, influencer marketing and quick commerce (over half of its e-commerce business) to hit a $200 million revenue target by 2030, leveraging Lacto Calamine, i-pill and new i-choose women's wellness range.
Why this matters
Piramal joins Indian FMCG peers consolidating around hero SKUs and quick commerce, doubling down on women's wellness with i-choose alongside legacy i-pill and Lacto Calamine franchises.
Retail-company signals steady at 3,934 over 90 days, reflecting sustained strategic repositioning activity.
Also reported by
- Mint — Same time